Naoto T. Ueno, Director at University of Hawai’i Cancer Center, shared on X about a recent paper by Toshiaki Iwase et al. published on Springer Nature:
“A study finds no difference in pCR between regimens with or without anthracyclines in HER2-positive inflammatory breast cancer (IBC). But those on anthracyclines had better disease control. More research needed!”
Title: Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study
Authors: Toshiaki Iwase, Nithya Sridhar, Megumi Kai, Wenli Dong, Yu Shen, Savitri Krishnamurthy, Anthony Lucci, H. T. Carisa Le-Petross, Azadeh Nasrazadani, Sadia Saleem, Rachel M. Layman, Vincente Valero, Debasish Tripathy, Wendy A. Woodward, Yee Chung Cheng, Faina Nakhlis, Jenifer R. Bellon, Filipa Lynce & Naoto T. Ueno
More posts featuring Inflammatory Breast Cancer.